Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200. In addition to NIH grants, PaxVax has raised $80 million from equity investors including Ignition Ventures, Ignition Growth Capital and the Blue Haven Initiative. "With its recent acquisition of Vivotif from Crucell, PaxVax has emerged as an exciting new player in the global travel vaccine market," said Martin Friedman, managing member of Pharmakon Advisors, which is providing the debt financing. Release